CDT Equity Inc. Announces Reverse Stock Split
Equity awards, convertible securities and warrants will receive proportional adjustments to share counts and applicable exercise prices.
Rhea-AI Summary
CDT Equity (CDT) will implement a 1-for-25 reverse stock split of its common shares, effective September 28, 2026. The split takes effect at 5:00 p.m. Eastern Time. Split-adjusted trading is expected to begin September 29 on the Nasdaq Capital Market under the same ticker. The company gives compliance with Nasdaq's bid-price rule as its reason.
Every 25 outstanding shares will become one share. Outstanding common shares will be reduced to approximately 1,013,515 after the split, while the $0.0001 per-share par value will remain unchanged. Holders entitled to fractional shares will receive proportional cash payments instead.
Positive
- None.
Negative
- None.
News Explained
The split will proportionally adjust equity-linked securities and plan share reserves; stockholders also authorized the board to set timing and ratios for future reverse splits.
CDT’s announced reverse split remains scheduled to take effect on
Separately, stockholders have approved future reverse splits, leaving their timing and exact ratios to the board.
Details
Market move: CDT -28.18% vs previous close. 1-for-25 reverse stock split
On Sep 25, the day this news came out, the latest delayed price for CDT is 28.18% below the previous close. Our momentum scanner has recorded 29 alerts for this stock so far that day. The latest delayed price is $0.09. Relative volume is exceptionally heavy at 21.3x the average.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
- Reverse split ratio
- 1-for-25
- Approved reverse split of common stock
- Effective time
- September 28, 2026 at 5:00 pm ET
- Reverse stock split
- Split-adjusted trading date
- September 29, 2026
- Expected to begin at market open under ticker CDT
- Post-split outstanding shares
- Approximately 1,013,515 shares
- Expected after the reverse stock split
Previous Stock split Reports
-
Earlier 1-for-10 reverse split addressed Nasdaq bid-price compliance; split-adjusted trading began July 20.
-
Earlier 1-for-25 split used the same ratio and projected approximately 4,722,450 post-split shares.
-
Earlier 1-for-8 reverse split projected approximately 1,352,448 outstanding shares after the split.
-
Earlier 1-for-15 reverse split reduced the outstanding share count to approximately 755,900.
-
Earlier 1-for-100 reverse split was announced to address Nasdaq's minimum bid-price requirement.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
cusip technical
convertible securities financial
street name financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
NAPLES, Fla. and CAMBRIDGE, United Kingdom, Sept. 25, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”), announces that its board of directors has approved a 1-for-25 reverse stock split of the Company’s common stock, to ensure continued compliance with the Nasdaq bid-price rule. The Company’s stockholders approved future reverse stock splits, their timing, and granted the board of directors authority to determine future exact split ratios.
The reverse stock split will become effective on September 28, 2026, at 5:00 pm, Eastern Time (the “Effective Time”), and the Company’s common stock is expected to begin trading on a reverse stock split-adjusted basis on The Nasdaq Capital Market (“Nasdaq”) at market open under the existing ticker symbol, “CDT” on September 29, 2026, the date which has been approved by Nasdaq for the effectiveness of such split.
As of the Effective Time, every 25 shares of the Company’s issued and outstanding common stock will be combined into one share of common stock. The par value per share of the Company’s common stock will remain unchanged at
The Company’s common stock will continue to trade on Nasdaq under the symbol “CDT” following the reverse stock split, with a new CUSIP number of 20678X700. After the effectiveness of the reverse stock split, the number of outstanding shares of common stock will be reduced to approximately 1,013,515. No fractional shares will be issued in connection with the reverse stock split, and stockholders who would otherwise be entitled to a fractional share will receive a proportional cash payment.
The Company’s transfer agent, Continental Stock Transfer & Trust Co., will serve as the exchange agent for the reverse stock split. Registered stockholders holding pre-reverse stock split shares of common stock electronically in book-entry form are not required to take any action to receive post-reverse stock split shares. Those stockholders who hold their shares in brokerage accounts or in “street name” will have their positions automatically adjusted to reflect the reverse stock split, subject to each broker’s particular processes, and will not be required to take any action in connection with the reverse stock split.
About CDT Equity Inc.
CDT Equity Inc. (NASDAQ: CDT) is a data-driven biopharmaceutical development company focused on identifying, enhancing, and advancing high-potential therapeutic assets through scientific innovation and strategic partnerships. Originally established as Conduit Pharmaceuticals, the company has evolved into a broader, more agile platform that leverages artificial intelligence, solid-form chemistry, and efficient asset repositioning to accelerate the development of novel treatments. Looking ahead, CDT is committed to creating shareholder value through licensing, strategic M&A, and positioning the company as a platform for transformative innovation.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of the federal securities laws. All statements other than statements of historical facts contained in this press release, including statements regarding the reverse stock split, CDT’s future results of operations and financial position, CDT’s business strategy, prospective product candidates, product approvals, research and development costs, timing and likelihood of success, plans and objectives of management for future operations, future results of current and anticipated studies and business endeavors with third parties, and future results of current and anticipated product candidates, are forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to; the effect that the reverse stock split may have on the price of the Company’s common stock; the ability or inability to maintain the listing of CDT’s securities on Nasdaq; the ability to recognize the anticipated benefits of the business combination completed in September 2023, which may be affected by, among other things, competition; the ability of the combined company to grow and manage growth economically and hire and retain key employees; the risks that CDT’s product candidates in development fail clinical trials or are not approved by the U.S. Food and Drug Administration or other applicable authorities on a timely basis or at all; changes in applicable laws or regulations; the possibility that CDT may be adversely affected by other economic, business, and/or competitive factors; and other risks and uncertainties identified in other filings made by CDT with the U.S. Securities and Exchange Commission. Moreover, CDT operates in a very competitive and rapidly changing environment. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond CDT’s control, you should not rely on these forward-looking statements as predictions of future events. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and except as required by law, CDT assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. CDT gives no assurance that it will achieve its expectations.
Investors
CDT Equity Inc.
Info@cdtequity.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
When does CDT Equity's reverse stock split take effect?
The 1-for-25 reverse stock split takes effect on September 28, 2026, at 5:00 p.m. Eastern Time. Split-adjusted trading is expected to begin at market open on September 29 under the existing ticker, CDT.
How will CDT Equity's reverse stock split affect equity awards and warrants?
The number of shares issuable upon exercise of equity awards, convertible securities and warrants will be adjusted proportionally, along with applicable exercise prices. Shares authorized and reserved under the company's equity incentive plans will also be adjusted proportionally.